HOME > BUSINESS > Lupin launches injectable iron formulations in India

Lupin launches injectable iron formulations in India

Pharma major Lupin Limited said it launched Iron Isomaltoside injectable iron formulation under two brand names “Isofer” and “Jilazo” in India.

Lupin acquired the exclusive rights to market, distribute and sell the injectable formulation from Denmark based Pharmacosmos A/S.

The product is currently marketed in 33 countries, including 21 European Union countries under the brand name “Monofer”.

Iron Isomaltoside 1000 is indicated for the treatment of iron deficiency anemia when oral iron preparations are ineffective or cannot be used and when there is a clinical need to deliver iron rapidly. It is also used across a wide range of disease states associated with iron deficiency.

Lupin will promote Isofer and JIilazo injectable formulations through its own sales force in India.

The Hematinics market in India is currently worth around Rs 1931 cr and is growing at 11%. Out of this, the iron injectable market size is valued at Rs 310 crores with growth of 17% (IMS MAT AUG 2016).

More than 1 billion people live with iron deficiency anaemia and it is the leading cause of death for an estimated 180,000 people every year. Iron deficiency is often associated with many chronic diseases such as renal diseases including chronic kidney disease, cancers including chemotherapy induced anaemia, gynaecologic disorders including abnormal uterine bleeding and gastrointestinal diseases including inflammatory bowel disease.

Pharmacosmos A/S s a family-owned, international healthcare company headquartered in Denmark.

It is a research-based company, its ongoing R&D programme focuses on improving patients from the iron deficiency with or without anaemia.

Pharmacosmos has subsidiaries in the Nordics, the UK and the US and its products are marketed in more than 80 countries across the world.

Lupin manufactures a wide range of branded & generic formulations, biotechnology products and APIs globally.

For the financial year ended 31st March, 2016, Lupin’s Consolidated sales and Net profit stood at Rs 136,539 million ($ 2.09 billion) and Rs 22,607 million ($ 345 million) respectively.

Follow ULTRA.news
Strides Shasun says Eris deal to help reprioritize business, lower debt Pharma major Strides Shasun said it agreed to sell its India branded generics business to Eris LifeSciences Limited for Rs 500 cr in cash."This transaction is the outcome of the company's portfolio reprioritization, to focus more sharply on larger regulated markets," it said...
Zydus gets nod for anti-inflammation drug in the US Pharma major Zydus Cadila said it received final approval from the USFDA to market an anti-inflammatory injection Ethacrynate Sodium in the US.The drug is used to decrease the Swelling (edema) caused by various disease conditions such as liver disease, kidney disease, conges...
Cipla launches ashtha inhaler therapy in the US Pharma giant Cipla Ltd said it received final approval for launching a generic version of Astrazeneca’s Pulmicort inhalation suspension for pediatric asthma in the US.The product is available for shipping immediately, Cipla said.Pulmicort Respules and generic equivalent...
Suven Life Sciences gets patents in USA, India and Hong Kong Pharma company Suven Life Sciences Ltd said it received new patents in India, USA and Hong Kong for neurological drugs.The patents -- one each in Hong Kong and the US and a couple in India -- are valid through 2032, 2030 and 2034."The granted claims of the patents include...
Zydus Cadila has an excellent quarter in Q2, PAT up 33% Pharma giant Zydus Cadila reported excellent numbers for the September quarter, led by rising US revenue that lifted its margins and profits.For the second quarter ended September 30, 2017, Zydus Cadila reported Earnings before Interest, Depreciation and Tax (EBIDTA) of Rs. 8...
Lupin gets USFDA warning on Goa, Indore plans, to affect new approvals Pharma major Lupin said it a warning letter from the US Food and Drug Administration for its formulations manufacturing facilities in Goa and Indore on Monday."We are deeply disappointed to hove received this outcome. While there will be no disruption of existing product sup...
Alembic Pharma buys US-based generics manufacturer Alembic Pharmaceuticals said it bought New Jersey-based generic drug developer Orit Laboratories LLC, which will bring seven approved generics and four applications with it.Orbit has "a team of eight highly experienced scientists," Alembic said, adding that the firm focuses ...
Lupin Q2 sales down 8%, PAT falls 31.3% Pharma major Lupin reported an 8% fall in Q2 revenue to Rs. 3,952 cr.Earnings before Interest, Tax, Depreciation and Amortization (EBITDA) for the quarter fell by 13% to 927 cr.Net profit was also down by 31.3% at Rs 455 cr in in the September quarter. The profit was high...
Cipla gets USFDA nod to launch kidney drug in the US Pharma giant Cipla said it received final approval to market a generic version of Genzyme’s kidney drug Renvela Tablets in the US.Renvela Tablets had US sales of approximately $1.85 billion for the 12-month period ending August 2017, according to IMS Health.The approval...
Lupin gets USFDA approval for generic ADHD drug Pharma Major Lupin said it received final approval from the United States Food and Drug Administration (FDA) to market a generic version of Concordia Pharmaceuticals Inc.’s ADHD drug Kapvay.It had annual sales of approximately USD 66 million in the US.Clonidine Hydrochlo...
Lupin buys US-based vaginosis drug maker for $150 mln Pharma major Lupin said that its US subsidiary, Lupin, Inc has acquired Symbiomix Therapeutics, LLC for a cash consideration of USD 150 million including a USD 50 million upfront and other time‐based payments.In addition, there are sales based contingent payments.Lupin h...
Suven Life Sciences gets patent for neuro drug Suven Life Sciences Ltd said it was granted a patent by New Zealand authorities for "a class of selective 5-HT4 compounds" that are being developed to treat neurodegenerative diseases.The compounds are being explored for use in cases of Alzheimer’s disease, Attention deficie...
USFDA returns Mylan-Biocon’s drug application for more data The U.S. Food and Drug Administration has sought more data before approving a chemotherapy compound submitted by Mylan and jointly developed by Biocon.The agency issued a 'complete response letter'. Such letters are issued when an FDA review an FDA review finds that an appli...
Lupin gets FDA nod to launch heart drug in the US Pharma manufacturer Lupin said it received approval to launch the generic version of US World Meds' Corgard heart drug.Nadolol Tablets USP, 20 mg, 40 mg, and 80 mg Tablets had annual sales of approximately USD 109.8 million in the US, the Indian drugmaker said.Lupin's N...
NATCO Pharma to sell multiple sclerosis drug in USA via Mylan NATCO Pharma Limited said it the US Food and Drug Administration approved the generic drug application filed by its marketing partner Mylan for injections used in the treatment of multiple sclerosis, a chronic inflammatory disease of the central nervous system.The drug, Glat...
Vivimed pharma unit gets Rs 270 cr investment from OrbiMed fund Pharmaceuticals and specialty chemicals maker Vivimed Labs said investment firm OrbiMed will invest $42.5 mn (Rs 270 cr) into its active pharmaceutical ingredients business.The investment will be into Vivimed Labs Mascarene Ltd, which is in turn the holding entity of the com...
Glenmark to launch Desonide topical ointment in US Glenmark Pharmaceuticals Inc said it has got the go-ahead to launch the generic version of Perrigo's anti-inflammation ointment Desonide Ointment in the US.Desonide Ointment, 0.05% had annual sales of approximately $23.4 million for the 12 month period ending July 2017, acco...
Biocon passes US-FDA inspection at Vishakapatanam plant Biocon said the plant inspection conducted by the US Food and Drug Administration at its Vishakapatanam plant passed without incident."US FDA inspected our Active Pharmaceutical Ingredients (API) manufacturing facility in Wishakhapatnam, Andhra Pradesh from September 11 to 1...
Zydus Cadila gets approval for two drugs in the US Zydus Cadila said it received the final regulatory approval to market anti-sleep drug Modafinil in the US, and tentative approval for bladder control drug Solifenacin Succinate.Unlike a final approval, tentative approvals don't allow the grantee to sell the drugs in the US m...
TCS launches AI-based IT incident prevention solution in Japan Tata Consultancy Services launched its artificial intelligence-based IT repair and prevention solution, ignio, in Japan."When System outages occur today, businesses dedicate vast resources to rectify the problem. Oftentimes, multiple teams are called together to identify the...